IL6 and COVID-19: Their poorer neurological status can be related to the complicated medical course from severe COVID-19 (i.e., ARDS requiring anti-IL-6 therapy), acute cardiac dysfunction (10), fatal ICH, and iatrogenic from heavy sedation, ventilator, and ECMO therapies.